Insider · CIK 0002147448
Defj, LLC
Files at RNAZ (Transcode Therapeutics, Inc.). First filing -, latest -.
In brief
Defj, LLC files SEC Form 4 as 10% owner at RNAZ (Transcode Therapeutics, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Defj, LLC has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 4 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Aug 3, 2026 | RNAZ Transcode Therapeutics, Inc. | CConversion Common Stock | +11,813,859 | - | - | 12,113,899 | Aug 5, 2026 |
| Aug 3, 2026 | RNAZ Transcode Therapeutics, Inc. | CConversion Common Stock | +2,020,582 | - | - | 14,134,481 | Aug 5, 2026 |
| Aug 3, 2026 | RNAZ Transcode Therapeutics, Inc. | CConversion Series A Non-Voting Convertible Preferred Stockderivative | -1,181 | $0.00 | $0 | 0 | Aug 5, 2026 |
| Aug 3, 2026 | RNAZ Transcode Therapeutics, Inc. | CConversion Series B Non-Voting Convertible Preferred Stockderivative | -202 | $0.00 | $0 | 0 | Aug 5, 2026 |
Questions about Defj, LLC
Answered from the filings on this page, as of the latest one.
Is Defj, LLC buying or selling?
Defj, LLC has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Defj, LLC's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Defj, LLC has 0.
Where does Defj, LLC file Form 4?
Defj, LLC has filed Form 4 at RNAZ (Transcode Therapeutics, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.